HeXun Biosciences , Ltd. Overview
Valuation check: 6986.TWO's ROE is 10.88%, above the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow10.88%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, 6986.TWO shows a ROE of 10.88%. That is above the Healthcare sector average of -100.59%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about -100.59%. HeXun Biosciences , Ltd. is at 10.88%, which is higher that average. That is roughly 110.8% above the sector mean. Use the comparison chart on this page to see how 6986.TWO stacks up against individual peers as well.
Check the historical chart to see whether 6986.TWO's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare HeXun Biosciences , Ltd. with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has HeXun Biosciences , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 10.88%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about -100.59%, while 6986.TWO is at 10.88%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
